TCR Constructs for Tumor Antigen Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective tools for analyzing diverse T cell receptor (TCR) repertoires in the context of highly polymorphic human leukocyte antigens (HLA) alleles, hindering the understanding of tumor-infiltrating T cell specificities and their therapeutic potential in cancer treatment.
Innovation Solution
Development of novel polypeptide constructs with specific binding affinity for antigens, including recombinant TCRs and antibodies, and engineered cells capable of recognizing cancer cells, utilizing bioinformatics tools like GLIPH2 to identify shared tumor antigens and cross-reactive T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If next-generation sequencing technologies are used to sequence large numbers of TCR, then sequencing cost and ease are improved, but analysis capability deteriorates due to the vast diversity of TCR sequences and polymorphic HLA alleles
Solution Approach 1:
The patent segments the complex TCR repertoire analysis problem into manageable components by focusing on specific CDR3 regions (CDR3α and CDR3β) rather than analyzing entire TCR sequences. This segmentation allows researchers to identify and analyze conserved motifs within the variable CDR3 regions, making the analysis of diverse TCR repertoires tractable while maintaining the ability to distinguish between different antigen specificities
Solution Approach 2:
The patent introduces computational algorithms as intermediary tools that bridge the gap between raw sequencing data and biological insight. These algorithms process large volumes of TCR sequence data, identify recurring CDR3 motifs, and predict antigen specificities, thereby enabling the analysis of diverse TCR repertoires without requiring direct manual interpretation of each sequence
2Measurement precision
If tools for analyzing diverse TCR repertoires in the context of highly polymorphic HLA alleles are developed, then understanding of T cell specificities improves, but device and method complexity increases
Solution Approach 1:
The patent applies local quality by focusing analysis efforts on the CDR3 regions of TCR sequences, which are the most variable and antigen-contacting portions. By concentrating computational resources on identifying motifs within these specific local regions rather than analyzing entire TCR sequences, the method achieves high specificity identification accuracy while keeping the analytical approach manageable
Solution Approach 2:
The patent changes the analytical parameters from examining entire TCR sequences to focusing on specific CDR3 motif characteristics. This parameter change involves identifying recurring amino acid patterns within CDR3 regions and using these motifs as the basis for predicting antigen specificity, thereby simplifying the analysis while improving precision in identifying T cell specificities
3Loss of information
If the specificities of tumor-infiltrating T cells are uncovered, then understanding of tumor-immune interactions improves, but the ability to translate this knowledge into therapeutic strategies remains limited due to lack of analytical tools
Solution Approach 1:
The patent performs preliminary action by developing computational methods to identify and catalog CDR3 motifs associated with specific antigen specificities before therapeutic development begins. By pre-processing and organizing TCR repertoire data into identifiable motif patterns, the patent creates a foundation that accelerates subsequent therapeutic development efforts, allowing researchers to quickly identify potential targets and design appropriate immunotherapies
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the identification of novel shared tumor antigens and cross-reactive T cells, potentially enhancing immunotherapy strategies by understanding T cell specificities and interactions with cancer cells.
Implementation Method 1
novel polypeptide constructs having binding affinity for a specific antigen
Data Source
AI summary
The present disclosure relates generally to polypeptide constructs, and particularly relate to T-cell receptor (TCR) constructs having binding affinity for a specific cognate antigen. The disclosure also provides compositions and methods useful for producing such constructs as well as methods for the diagnosis, prevention, and/or treatment of conditions associated with cells expressing the cognate antigen recognized by the polypeptide constructs.